Dapagliflozin/saxagliptin - AstraZeneca
Alternative Names: Qtern; Saxa/dapa; SaxaDapa; SaxaDapa FDC; Saxagliptin/dapagliflozinLatest Information Update: 05 Nov 2023
At a glance
- Originator Bristol-Myers Squibb
- Developer AstraZeneca
- Class Adamantanes; Antihyperglycaemics; Chlorobenzenes; Cycloparaffins; Dipeptides; Glucosides; Nitriles; Organic bridged compounds; Piperidines; Pyrans; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 02 Dec 2019 9277761 : No update
- 30 Jan 2019 Chemical structure information added
- 30 Jun 2018 AstraZeneca completes a phase IIIb trial in Type-2 diabetes mellitus (Adjunctive treatment) in USA (PO) (NCT02613897)